Left ventricular hypertrophy and linked cardiovascular risk factors among Congolese licensed civilian aircrew

Abstract

Objective: To assess the prevalence of left ventricular hypertrophy (LVH) and linked cardiovascular risk factors in civilian aircrew.

Methods: Cardiovascular risk factors were assessed among flight and cabin crew undergoing routine clinical and biological evaluation for initial or renewal of aeromedical license. The evaluation also included a standard 12-lead ECG and echocardiography. Echo-based LVH was LVM ≥ 49 g/m^2.7 (men) or ≥ 45 g/m^2.7 (women). LVH was categorized as mild (men: 49-55 g/m^2.7; women: 45-51 g/m^2.7), moderate (men: 56-63 g/m^2.7; women: 52-58 g/m^2.7), or severe (men: ≥ 64 g/m^2.7; women: ≥ 59g/m^2.7) according to Lang’s report.

Results: Among the 379 aircrew members (70.4% men; 23% Caucasians; 62.5% flight crew; mean age 40.6 ± 12.8 years), LVH was present in 36 individuals (9.5%) with mild, moderate and severe pattern observed respectively in 19.4%, 33.3% and 47.2% of the cases. The rate of LVH amounted to 16.7% in normotensive subjects, 25.0% in those with prehypertension, and 58.3% among hypertensive individuals. In addition to age of 40-59y (OR: 8.48; 95% CI: [2.23-12.23]; p =.002) or more (4.22 [1.57-11.35]; p =.004), hypertension (3.55 [1.50 - 8.41]; p =.004), overweight/obesity (5.33 [1.14 - 25.05]; p =.034) and hyperuricemia (5.05 [2.11 - 12.09]; p =.001), all well-known constituents of the metabolic syndrome, were the main factors significantly associated with LVH.

Conclusion: The frequency and link of LVH to the components of the metabolic syndrome highlights the need for a comprehensive approach to the management of cardiovascular risk factors in civilian aircrew.

Keywords

Left ventricular hypertrophy / Associated factors / Civilian aircrew

References

[1] Levy G, Anderson KM, Savage DD, et al. Echocardiographically detected left ventricular hypertrophy: prevalence and risk factors. The Framingham study. Ann Intern Med. 1988; 108: 7-13.

[2] Okwuosa TM, Soliman EZ, Lopez F, et al. Left ventricular hypertrophy and cardiovascular disease risk prediction and reclassification in blacks and whites: the Atherosclerosis Risk in Communities Study. Am Heart J. 2014; 169(1): 155-61.e5. PMid:25497261. https://doi.org/10.1016/j.ahj.2014.09.013

[3] Bombelli M, Ronchi I, Volpe M, et al. Prognostic value of serum uric acid: new-onset in and out-of-office hypertension and long-term mortality. J Hypertens. 2014; 32: 1237-1244. PMid:24675682. https://doi.org/10.1097/HJH.0000000000000161

[4] Kannel WB, Gordon T, Offutt D. Left ventricular hypertrophy by electrocardiogram. Prevalence, incidence, and mortality in the Framingham study. Ann Intern Med. 1969; 71: 89-105. PMid:4239887. https://doi.org/10.7326/0003-4819-71-1-89

[5] Levy D, Garrison RJ, Savage DD, et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med. 1990; 322: 1561-1566. PMid:2139921. https://doi.org/10.1056/NEJM199005313222203

[6] Ommen SR, Nishimura RA, Appleton CP, et al. Clinical utility of Doppler echocardiography and tissue Doppler imaging in the estimation of left ventricular filling pressures. Circulation. 2000; 102: 1288-1794. PMid:11023933. https://doi.org/10.1161/01.CIR.102.15.1788

[7] Soliman EZ, Prineas RJ. Antihypertensive therapies and left ventricular hypertrophy. Curr Hypertens Rep. 2017; 19(10): 79. PMid:28929454. https://doi.org/10.1007/s11906-017-0777-3

[8] Bang CN, Soliman EZ, Simpson LM, et al. ALLHAT Collaborative Research Group. Electrocardiographic Left Ventricular Hypertrophy Predicts Cardiovascular Morbidity and Mortality in Hypertensive Patients: The ALLHAT Study. Am J Hypertens. 2017 Sep 1; 30(9): 914-922. PMid:28430947. https://doi.org/10.1093/ajh/hpx067

[9] Pascal MB, Jean-Renée Jr M’Buyamba-Kayamba, Daniel L, et al. Cardiovascular Risk Factors among the Inhabitants of an Urban Congolese Community: Results of the VITARAA Study. https://doi.org/10.1016/j.ijcme.2014.07.003

[10] M’Buyamba-Kabangu JR, Biswika T, Thijs L, et al. In-hospital mortality among black patients admitted for hypertension-related disorders in Mbuji Mayi, Congo. Am J Hypertens. 2009; 22: 643-648. PMid:19282818. https://doi.org/10.1038/ajh.2009.47

[11] Bayauli MP, Lepira FB, Kayembe PK, et al. Left ventricular hypertrophy and geometry in type 2 diabetes patients with chronic kidney disease. An echographic study. Cardiovascular Journal of Africa. 2012; 23(2): 73-77. PMid:22447475. https://doi.org/10.5830/CVJA-2011-028

[12] Buila NB, Bantu JM, Kabanda GK, et al. Atherosclerotic Cardiovascular Disease Short-Term Risk Estimate among Civilian Licensed Aircrew. World Journal of Cardiovascular Diseases. 2019; 9, 92-108. https://doi.org/10.4236/wjcd.2019.92010

[13] Finucane MM, Stevens GA, Cowan M, et al. National, regional, and global trends in body mass index since 1980: Systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. Lancet (London, England). 2011; 377(9765): 557-567. https://doi.org/10.1016/S0140-6736(10)62037-5

[14] Pischon T, Boeing H, Hoffmann K, et al. General and abdominal adiposity and risk of death in Europe. N Engl J Med. 2008; 359(20): 2105-2120. PMid:19005195. https://doi.org/10.1056/NEJMoA08018914

[15] Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. European Heart Journal. 2018; 39(33): 3021-3104. PMid:30165516. https://doi.org/10.1093/eurheartj/ehy339

[16] Lang RM, Badano L, Afilalo J,Chamber Quantification Writing Group, American Society of Echocardiography’s Guidelines, Standards Committee, European Association of Echocardiography. Recommendations for cardiac chamber quantification by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015; 28: 1-39. PMid:25559473. https://doi.org/10.1016/j.echo.2014.10.003

[17] Cuspidi C, Meani S, Negri F, et al. Indexation of left ventricular mass to body surface area and height to allometric power of 2.7: Is the difference limited to obese hypertensives. Journal of Human Hypertension. 2009; 23: 728-34. PMid:19322202. https://doi.org/10.1038/jhh.2009.16

[18] Barbieri A, Bursi F, Mantovani F, et al. Prognostic impact of left ventricular mass severity according to the classification proposed by the American Society of Echocardiography/European Association of Echocardiography. J Am Soc Echocardiogr. 2011; 24: 1383-1391. PMid:21975437. https://doi.org/10.1016/j.echo.2011.08.012

[19] Marwick TH, Gillebert TC, Aurigemma G, et al. Recommendations on the use of echocardiography in adult hypertension: a report from the European Association of Cardiovascular Imaging (EACVI) and the American Society of Echocardiography (ASE), European Heart Journal - Cardiovascular Imaging. 2015 June; 16(6): 577-605.

[20] Friedelwald WT, Levy RI, Fredrickson DS. Estimation of the Concentration of Low-Density Lipoprotein Cholesterol in Plasma without Use of the Preparative Ultracentrifuge. Clinical Chemistry. 1972; 18: 499-502. https://doi.org/10.1093/clinchem/18.6.499

[21] ADA American Diabetes Association (2010). Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 2010; 33: S62. PMid:20042775. https://doi.org/10.2337/dc10-S062

[22] Alberti KGMM, Eckel RH, Grundy SM, et al. Harmonizing the Metabolic Syndrome: A Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009; 120: 1640-1645. PMid:19805654. https://doi.org/10.1161/CIRCULATIONAHA.109.192644

[23] Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018; 39: 3021. PMid:30165516. https://doi.org/10.1093/eurheartj/ehy339

[24] Ching S, Chia Y, Wan AW. Prevalence and Determinants of Left Ventricular Hypertrophy in Hypertensive Patients at a Primary Care Clinic. Malaysian Family Physician. 2012; 7: 3.

[25] Daniel P, Juni P, Egger M, et al. Bachmann LM. Accuracy of electrocardiography in diagnosis of left ventricular hypertrophy in arterial hypertension: systematic review. British Medical Journal. 2007; 335(7622): 711. PMid:17726091. https://doi.org/10.1136/bmj.39276.636354.AE

[26] Fragola PV, De Nardo D, Calo L, et al. Use of the signal-averaged QRS duration for diagnosing left ventricular hypertrophy in hypertensive patients. Int J Cardiol. 1994; 44(3): 261-70. https://doi.org/10.1016/0167-5273(94)90290-9

[27] Mvunzi TS, Lubenga Y, Lepira FB, et al. Prevalence of Circadian Blood Pressure Patterns and Factors Associated with Non-Dipping among Black Patients with Untreated and Treated Hypertension: A Cross-Sectional Study. World Journal of Cardiovascular Diseases. 2017; 11: 399-412. https://doi.org/10.4236/wjcd.2017.711038

[28] Mpembe BC, Lepira FB, Mbutiwi FI et al. Left Ventricular Structure, Geometry and Systolic Function among Hypertensive Black Patients with Reduced Kidney Function. World Journal of Cardiovascular Diseases. 2015; 5: 287-295. https://doi.org/10.4236/wjcd.2015.510032

[29] Martinez MA, Sancho T, Armada E, et al. Vascular Risk Working Group Grupo Monitorizacíon Ambulatoria de la Presión Arterial (MAPA)-Madrid. Prevalence of left ventricular hypertrophy in patients with mild hypertension in primary care: impact of echocardiography on cardiovascular risk stratification. Am J Hypertens. 2003; 16: 556-563. https://doi.org/10.1016/S0895-7061(03)00859-8

[30] Dai DF, Chen T, Johnson SC, et al. Rabinovitch. Cardiac Aging: From Molecular Mechanisms to Significance in Human Health and Disease. 2012. PMid:22229339. https://doi.org/10.1089/ars.2011.4179

[31] Santos M, Shah AM. Alterations in Cardiac Structure and Function in Hypertension. Curr Hypertens Rep. 2014; 16: 428. PMid:24639061. https://doi.org/10.1007/s11906-014-0428-x

[32] Cuspidi C, Rescaldani M, Sala C, et al. Left-ventricular hypertrophy and obesity: A systematic review and meta-analysis of echocardiographic studies. J Hypertens. 2014; 32: 16-25. PMid:24309485. https://doi.org/10.1097/HJH.0b013e328364fb58

[33] Mehta SK, Rame JE, Khera A, et al. Left ventricular hypertrophy, subclinical atherosclerosis, and inflammation. Hypertension. 2007; 49: 1385-1391. PMid:17404181. https://doi.org/10.1161/HYPERTENSIONAHA.107.087890

[34] Moreira MC, Pinto IS, Mourão AA, et al. Does the sympathetic nervous system contribute to the pathophysiology of metabolic syndrome? Front Physiol. 2015; 6: 234. PMid:26379553. https://doi.org/10.3389/fphys.2015.00234

[35] Balasubramanian P, Hall D, Subramanian M. GeroScience. Sympathetic nervous system as a target for aging and obesity-related cardiovascular diseases. 2019; 41: 13. PMid:30519806. https://doi.org/10.1007/s11357-018-0048-5

[36] Seymour R, Blaylock A. The Principle of Laplace and Scaling of Ventricular Wall Stress and Blood Pressure in Mammals and Birds. Physiological and Biochemical Zoology: PBZ. 2000; 73: 389-405. PMid:11009393. https://doi.org/10.1086/317741

[37] Mehta SK, Rame JE, Khera A, et al. Left ventricular hypertrophy, subclinical atherosclerosis, and inflammation. Hypertension. 2007; 49: 1385-1391. PMid:17404181. https://doi.org/10.1161/HYPERTENSIONAHA.107.087890

[38] Bayauli MP, LEPIRA FB, KAYEMBE PK, et al. Left ventricular hypertrophy and geometry in type 2 diabetes patients with chronic kidney disease. An echographic study. Cardiovascular Journal of Africa. 2012; 23(2): 73-77. PMid:22447475. https://doi.org/10.5830/CVJA-2011-028

[39] Mazzali M, Kanellis J, Han L, et al. Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am J Physiol Renal Physiol. 2002; 282: F991-F997. PMid:11997315. https://doi.org/10.1152/ajprenal.00283.20011